Xencor Jumps 20% After Kidney Cancer Results and Target Increase

Why Xencor Stock Jumped Today

Xencor shares rose 20% to $30.12 by early afternoon after updated results for its experimental kidney cancer drug XmAb819. The findings supported plans for larger trials. Investment firm Wedbush also raised its estimate of what the shares could be worth.

What Xencor Inc. Does

Xencor develops engineered antibodies, proteins designed to bind selected targets, for cancer and diseases where the immune system attacks healthy tissue. XmAb819 connects a cancer target with immune cells that can attack it.

XmAb819 Kidney Cancer Trial Results

In Phase 1, an early human study of safety and potential activity, Xencor reported a 45.5% confirmed response rate. That means tumors shrank enough to meet study rules, with later checks confirming the change. The six-month estimate of patients alive without their cancer worsening was 82%.

Xencor Plans Larger Kidney Cancer Trial

Xencor plans a global study comparing its drug with Tivozanib, another kidney cancer treatment. Patients will be assigned to different treatment groups for comparison. That test can show whether the early findings hold up across more patients.

Wedbush Raises Xencor Price Target

Wedbush raised its price target to $45 from $30 and kept its positive rating. Analysts polled by FactSet, a financial data provider, had an average target of $33.58. These estimates express expectations, not guaranteed future prices.

Quick Financial Overview

Xencor has real revenue but remains unprofitable, with $2.24B in market value, the total value of its shares. That makes it a mid-cap, meaning a middle-sized listed company. Its latest report showed $456.5M in cash, cash equivalents, and short-term investments as of June 30, 2026, money held as cash or readily accessible investments, enough for about twenty-five months at the recent spending rate.

Xencor Revenue and Earnings

The latest quarter brought $51.2M in revenue and a net loss of $21.7M. Revenue is company-wide, not evidence that XmAb819 is already an approved product.

Xencor Quarterly Cash Use

Xencor used $55.7M to run its business and fund development during that quarter. Larger trials make spending an important part of the business story alongside clinical progress.

Xencor Stock Extends Its Longer Climb

Xencor shares are up 130% over the past half-year, so today’s jump extends an existing climb. It was the biggest daily move in the last year. Trading reached about 6.3 million shares, showing broad participation in the repricing.

Conclusion

The next dated milestone is a planned discussion with the U.S. drug regulator in the first half of next year about earlier approval. That route could use early evidence but would still require later confirmation; regulator support would clarify the path, while objections could require more testing. Xencor’s reported funding position covers the wait.